RecruitingPhase 2NCT05136755

NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder


Sponsor

China Medical University Hospital

Enrollment

50 participants

Start Date

Jan 25, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a drug that works on the NMDA receptor in the brain (which regulates mood) can help people with major depression who have not responded to standard antidepressants. **You may be eligible if...** - You have been diagnosed with major depressive disorder (MDD) - At least one antidepressant has not worked for you at an adequate dose and duration - Your current medications have been unchanged for at least 8 weeks - Your depression symptoms score at a moderate-to-severe level on a clinical scale **You may NOT be eligible if...** - You have other psychiatric conditions that may confound the study - You recently changed antidepressant medications (within 8 weeks) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNMDAE

Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD

DRUGPlacebo Cap

Use of placebo as a comparator


Locations(1)

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05136755


Related Trials